Nonetheless, since, overall, the prognosis of ER/PR-negative tumors is relatively poorer than for ER/PR-positive, targeting TIMAP may present a new therapeutic opportunity in treatment of challenging subtypes of breast cancer. Here, PPP1R16B is linked to breast carcinoma.